Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Ipsen S.A. (OP: IPSEF )

125.37 UNCHANGED
Last Price Updated: 11:08 AM EDT, Oct 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 125.37
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 125.37
Today's Range 125.37 - 125.37
52wk Range 110.36 - 125.37
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Third Time Lucky: Exelixis' Cabozantinib Combo Therapy Aces Pivotal Study In Prostate Cancer Patients
Roche Holdings AG (OTC: RHHBY), Exelixis Inc (NASDAQ: EXEL), and Ipsen&nbs 
Via Benzinga
What Now After FDA AdComm Rebuke for Intercept Pharmaceutical? Analyst Says Approval Of Intercept's 'OCA In NASH May Never Occur
On Friday, FDA's Gastrointestinal Drugs Advisory Committee voted 12 to 2—with two abstentions—that the benefits of Intercept Pharmaceutical Inc's ICPT Ocaliva 25 mg, also known as Obeticholic acid... 
Via Benzinga

Performance

YTD
+6.93%
+6.93%
1 Month
N/A
N/A
3 Month
N/A
N/A
6 Month
+6.60%
+6.60%
1 Year
+6.93%
+6.93%

More News

Read More
France-Based Ipsen Acquires Albireo Pharma Enriching Its Rare Disease Portfolio, Pipeline
Via Benzinga
Why Merrimack Shares Are Surging Over 200% Today?
Via Benzinga
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
Via Benzinga
Why Is Epizyme (EPZM) Stock Up 75% Today?
Via InvestorPlace
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
Via Benzinga
Ipsen - Exelixis' Cabometyx Scores European Approval As Second-Line Treatment For Thyroid Cancer
Via Benzinga
EMA's Scientific Committee Backs Expanded Use Of Exelixis, Ipsen's Cabometyx In Thyroid Cancer
Via Benzinga
Ipsen's Sohonos Scores Canadian Approval For Rare Connective Tissue Disease
Via Benzinga
Genfit Shares Rally After Ipsen Buys Rights To Its Late-Stage Kidney Disease Treatment Hopeful
Via Benzinga
Ipsen Stock Declines After Pulling Rare Disease Application
Via Benzinga
Exposures Product Safety
Exicure Stock Surges On Over $1B Option Licensing Pact With Ipsen For Rare Neurodegenerative Disorders
Via Benzinga
Ipsen Beefs Up Pre-Clinical Oncology Pipeline With Over $850M Deal With BAKX Therapeutics
Via Benzinga
Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.